Drug companies do not simply invent medicines. They engineer legal structures designed to convert twenty years of patent protection into
Crack the Patent Wall: How Hard Data Beats Big Pharma’s IP Strategy Every Time Read Post »
The Counterintuitive Move That Makes Perfect Business Sense A brand pharmaceutical company holds an approved drug. No generic competitor has
A forensic comparison of the 505(b)(2) and 505(j) regulatory strategies that separate profitable pharmaceutical launches from expensive cautionary tales. The
A forensic guide to pharmaceutical life cycle extension: the IP strategies, regulatory mechanics, and commercial execution frameworks that separate drugs
Five Plays That Keep Your Blockbuster Drug Alive After the Patent Clock Runs Out Read Post »
Somewhere in the patent office’s public records, there is a graveyard. It has no physical address and no memorial plaques,
When Big Pharma Walks Away: What Abandoned Patents Reveal About Pipeline Priorities Read Post »
Pharmaceutical executives are losing control of their product narratives. While marketing teams focus on search engine optimization and field sales,
Stop AI Hallucinations From Destroying Your Drug Brand Value Read Post »
Pfizer’s finance team did not need a news alert to know Lipitor was in trouble. By 2010, the company’s own
Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat
A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
Sign in or create a free account to read this DrugPatentWatch article
